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ABSTRACT
Context: Colorectal cancer (CRC) surgical treatment delay (TD) has been associated with mortality and morbidity; however,
disparities by TD profiles are unknown.
Objectives: This study aimed to identify CRC patient profiles of surgical TD while accounting for differences in sociodemographic, health insurance, and geographic characteristics.
Design: We used latent class analysis (LCA) on 2005-2015 Tennessee Cancer Registry data of CRC patients and observed indicators that included sex/gender, age at diagnosis, marital status (single/married/divorced/widowed), race
(White/Black/other), health insurance type, and geographic residence (non-Appalachian/Appalachian).
Setting: The state of Tennessee in the United States that included both Appalachian and non-Appalachian counties.
Participants: Adult (18 years or older) CRC patients (N = 35 412) who were diagnosed and surgically treated for in situ
(n = 1286) and malignant CRC (n = 34 126).
Main Outcome Measure: The distal outcome of TD was categorized as 30 days or less and more than 30 days from
diagnosis to surgical treatment.
Results: Our LCA identified a 4-class solution and a 3-class solution for in situ and malignant profiles, respectively. The
highest in situ CRC patient risk profile was female, White, aged 75 to 84 years, widowed, and used public health insurance
when compared with respective profiles. The highest malignant CRC patient risk profile was male, Black, both single/never
married and divorced/separated, resided in non-Appalachian county, and used public health insurance when compared with
respective profiles. The highest risk profiles of in situ and malignant patients had a TD likelihood of 19.3% and 29.4%,
respectively.
Conclusions: While our findings are not meant for diagnostic purposes, we found that Blacks had lower TD with in situ
CRC. The opposite was found in the malignant profiles where Blacks had the highest TD. Although TD is not a definitive
marker of survival, we observed that non-Appalachian underserved/underrepresented groups were overrepresented in the
highest TD profiles. The observed disparities could be indicative of intervenable risk.
KEY WORDS: cancer health disparities, colorectal cancer, latent class analysis, person-centered approach, treatment
delay
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A

pproximately 53 200 individuals will die
from colorectal cancer (CRC) in the United
States in 2020, second only to lung cancer.1
While declines in CRC incidence and mortality rates
have been observed in the United States1,2 due to
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improvements in early detection and treatment, as
well as changes in lifestyle behaviors such as decreased
tobacco use, disparities in outcomes continue to exist by race/ethnicity and socioeconomic status (SES).3-7
Studies have found disparities when comparing Black
with White patients, as Black patients were more
likely to be diagnosed with an advanced stage of CRC
and less likely to receive treatment.8-10 Cancer health
disparities could be attributable to early diagnosis of
cancer and treatment initiation that may impact patient survival and quality of life.11,12 According to the
American Cancer Society,13 the 5-year relative survival
rate for early-stage CRC is around 90%; yet, only 4 of
10 patients with CRC are detected at this stage. This
high level of survival rate for patients with early stage
of CRC suggests the importance of early detection and
treatment of CRC.
Treatment delay (TD) refers to the time from CRC
diagnosis to initiation of surgical treatment and has
been associated as a predictor of survival that affects
a substantial proportion of patients with CRC.14-16
A variety of factors stemming from patient characteristics, practitioners’ expertise, the health care
referral system, tumor biology, chemical toxicities
from chemotherapy, and clinical course have been
well-documented as complex underlying reasons for
TD.14,15,17 Nonetheless, studies focusing on the impact
of TD on CRC mortality and survival have reported
inconsistent results.15,18-25 For instance, in a systematic review by Hangaard Hansen et al,26 4 of the 5
studies on colon cancer delays showed no association between TD and overall survival. Earlier studies
investigating the influence of diagnostic and therapeutic delays concluded that, taken together, longer CRC
delays were not associated with better prognosis.27
When colon and rectal cancers are analyzed separately, however, statistically significant relationships
exist between diagnosis and TDs.28
Studies have indicated that TD is associated with
unfavorable outcomes, especially when diagnosis-totreatment intervals (DTIs) are taken into account.22-24
The inconsistencies in TD findings could be attributed to variations in DTIs,15,18,19,23,24 including
differences in sample sizes and stratification by cancer staging,15 surgical complications,18 comorbidities
during treatment,18,20 waiting time,18 and geographic
residence.29-31 Lee et al15 examined the effect of length
of time from diagnosis to treatment on CRC survival
in newly diagnosed patients using the Taiwan Cancer Registry Database and found consistent decrease
in survival with increasing TD across all CRC stages
(I-IV). Pruitt et al25 assessed the association between
diagnosis and TDs on all-cause CRC-specific death
using Surveillance, Epidemiology, and End Results
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(SEER) data and Medicare claims files to conclude
that TD up to 120 days did not increase the risk
of death. Conversely, a systematic review and metaanalysis by Hanna et al32 found that a 4-week delay in
cancer treatment was associated with increased mortality across various treatment modalities, including
surgery, for colon and rectum cancer. Using the South
Australian clinical registry to examine the association between time to treatment of CRC and survival,
Roder et al18 reported better survival within 2 years
for diagnosis to treatment of more than 30 days than
of 30 days or less.
Furthermore, when considering CRC patients in the
US state of Tennessee, there are some generalizable
factors such as social determinants that affect timing
and access to treatment to the Appalachian region.33
Tennessee has a unique geographical context, that is,
Appalachia and subsequent regions, with limited studies having found a complex relationship with cancer
incidence and mortality.34 For instance, while cancer mortality has been found to be in decline in the
United States in general, disparities have been found in
Appalachian regions where rural Appalachia had the
highest cancer incidence compared with urban nonAppalachian areas.30 Specifically in the Appalachian
regions (ie, Northern, Central, Southern), CRC incidence was found to be higher than the rest of the
US.29 Yet, there are regional variations of cancer incidence within the Appalachian region, in particular
with the Central and Southern regions, of which Tennessee is part of but not included.29 Cancer health
disparities also occur within Appalachian and between Appalachian regions.29,30,35
Cancer disparities can be accounted for the Appalachian regions by geographic and ecological characteristics such as residence and neighborhood, as
well as availability and health care access disparities that include diagnostic and treatment services,
health insurance type, and recommendations leading
to cancer TD in addition to the social determinants
of health.30,36,37 While TD does not generally equate
to increased mortality, surgical TD may be associated with CRC disparities by increased morbidity
and decreased quality of life.38-40 Moreover, little is
known about Tennessee and CRC TD, as such our
purpose was not to make a clinical recommendation but to identify subgroup profiles of TD and
possible social determinants within profiles. To fill
this critical knowledge gap, the objective of this
study was to apply latent class analysis (LCA) to
comprehensively identify disparities and assess the
profiles of CRC patients who experience surgical TD
using the Tennessee Cancer Registry (TCR) data.
LCA is a person-centered approach that allows the
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identification of individual group profiles based on
a set of observed factors. Using LCA, we identified
and compared risk profiles of surgical TD in both in
situ and malignant CRC patients while accounting for
differences in sociodemographic and health insurance
characteristics.

Methods
Tennessee Cancer Registry and study population
The TCR is located within the Tennessee Department
of Health (TDH) and is dedicated to collecting comprehensive information on all patients diagnosed with
and/or treated for cancer in the state (https://www.tn.
gov/health/health-program-areas/tcr.html). The TCR
is a gold-certified registry by the North American Association of Central Cancer Registries (NAACCR),
indicating it has met the highest national standards of
data completeness and quality. It has maintained these
high standards of data completeness and quality since
2005.
The study population included Tennessee residents
18 years or older with a primary confirmed CRC
diagnosis according to ICD-O-3 (International Classification of Diseases for Oncology, Third Edition)
codes (ie, C180-189, C199, C209, C260), who had
surgical treatment, and were reported to the TCR between January 1, 2005, and December 31, 2015. The
population-based sample (N = 35 412) included in
situ (n = 1286) and malignant (n = 34 126) CRC subsamples. The TDH Institutional Review Board (IRB)
approved the research protocol on February 1, 2018
(TDH-IRB 1057486), and all analytical coding is
available upon request. Data used for this analysis are
restricted but available by request to the TDH TCR
(https://www.tn.gov/education/data/data-downloads/
request-data.html). All analytical files are available by
request. The National Institutes of Health, Intramural
Research Program IRB, Human Research Protections
Program, Office of Human Subjects Research Protections, determined that our protocol did not involve
human subjects and was excluded from IRB review
(18-NIMHD-00722).

Measures
Outcomes: In situ and malignant colorectal
cancer surgical treatment delay
On the basis of the literature,15,18,41 the distal outcome of TD was categorized as (1) 30 days or less,
and (2) more than 30 days since diagnosis using date
of diagnosis of disease to the beginning of surgical treatment. This approach provides a less biased
model because algorithms, not the researcher, group
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variables into classes or risk subgroups based on the
similar characteristics.
Latent variable of colorectal cancer delay using
sociodemographic characteristics
The latent construct of CRC TD included sociodemographic characteristics obtained from the TCR
were sex/gender, age, marital status, health insurance
type, race, and county of residence. While sex/gender
was assessed as a dichotomous variable (male and
female), age was assessed as a categorical variable
based on the US Preventive Services Task Force recommendations for CRC screening age (ie, <50, 50-74,
75-84, and ≥85 years).42 Marital status was categorized as single/never married, married/common
law, divorced/separated, and widow/widower. Health
insurance was based on whether the patient had
no insurance/self-paid, public insurance (eg, Medicaid, Medicare), or private insurance (eg, Preferred
Provider Organization, Health Maintenance Organization). Race was classified as White, Black, or
other. Other race included Asian or Pacific Islander
and American Indian/Native Alaskan. Place of residence was categorized into 2 groups on whether patient resided in an Appalachian or non-Appalachian
county.
Latent class/statistical analysis
A model comparison approach was used to determine the number of classes. We created multiple
models (ie, 2-, 3-, 4-, 5-class solutions for in situ
cases and up to 4-class solutions for malignant cases)
that helped select the best model for interpretation.
Model fit comparisons were based on the following
criteria: (1) Bayesian information criterion (BIC); (2)
sample size–adjusted BIC (ssa-BIC); and (3) high entropy (ie, the acceptable quality of classification, and a
clear indication for separation of classes).43 All LCAs
were conducted using Mplus version 8.4 (Muthén &
Muthén, Los Angeles, California). See Table 1 for
more detail. The classes were named on the basis
of the relative surgical TD categories (ie, ≤30 and
>30 days) from CRC diagnosis to surgical treatment
initiation.

Results
Patient sociodemographic characteristics
A total of 35 415 in situ and malignant CRC patients
were included. A majority of the cases were malignant (96.3%) at the time of diagnosis (Table 2). Most
in situ patients were White (84.4%), male (53.9%),
aged 50 to 74 years (69.6%), married (62.0%),
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TABLE 1
Latent Class Analysis of Colorectal Cancer Delay Group Model Fit Comparisons
In Situ CRC (N = 1 286)
1-Class solution
2-Class solution
3-Class solution
4-Class solution

Malignant CRC (N = 34 126)

BIC

ssa-BIC

Entropy

BIC

ssa-BIC

Entropy

11 816.06
11 571.62
11 572.93
11 600.16

11 774.76
11 485.86
11 442.69
11 425.46

...
0.677
0.612
0.672

345 575.23
334 940.54
331 683.83
...

345 533.92
334 854.73
331 553.54
...

...
0.637
0.706
...

Abbreviations: BIC, Bayesian information criterion; CRC, colorectal cancer; ssa-BIC, sample size–adjusted Bayesian information criterion.

with health insurance (70.2%), and residing in Appalachian county. The characteristics of malignant
CRC patients are similar to in situ CRC patients
except that the majority of them resided in nonAppalachian county. See Table 2 for further details.
TABLE 2
Descriptive Statistics of In Situ and Malignant Samples
(N = 35 415)

Sex/gender
Male
Female
Age at diagnosis
<50 y
50-74 y
75-84 y
≥85 y
Marital status
Single/never married
Married/common law
Divorced/separated
Widow/widower
Health insurance type
No insurance/self-pay
Public insurance
Private Insurance
Race
White
Black
Other
County of residence
Non-Appalachian
Appalachian
Treatment delay
≤30 d
>30 d

In situ
(N = 1 286)

Malignant
(N = 34 126)

n

%

n

%

693
593

53.9
46.1

17 631
16 492

51.7
48.3

95
895
235
61

7.4
69.6
18.3
4.7

3 743
20 899
7 015
2 469

11.0
61.2
20.6
7.2

103
570
98
149

11.2
62.0
10.7
16.2

3 785
15 416
2 820
5 034

14.0
57.0
10.4
18.6

21
810
323

1.8
70.2
28.0

1 466
21 259
8 169

4.7
68.8
26.4

1 085
190
11

84.4
14.8
0.9

28 628
5 059
439

83.9
14.8
1.3

634
652

49.3
50.7

18 114
15 994

53.1
46.9

1 087
199

84.5
15.5

26 136
7 990

76.6
23.4

Latent class analysis on in situ subgroups treatment
delay
As seen in Table 3, TD among in situ CRC patients
revealed a 4-class solution with entropy of 0.67 (N =
1286). Class 1, or the lowest TD in situ profile, constitutes 45% of the subsample. This subgroup had high
conditional probabilities of being 50 to 74 years of age
at the time of diagnosis (85.4%), married/in a common law marriage (68.6%), mostly White (94.9%),
male (55.7%), and more likely to have private health
insurance (50.5%). In addition, this profile had a
high probability of residing in an Appalachian county
(53.9%). Class 1 also had the lowest conditional
probability to experience TD of more than 30 days
(12.4%).
Class 2, or the medium-low TD in situ profile, was
exclusively Black (100%) and had high conditional
probabilities of being between 50 and 74 years of age,
being female (52.2%), and have public health insurance (58.3%). This class had the highest conditional
probabilities of being single/never married (33.1%),
divorced/separated (17.3%), and residing in a nonAppalachian county (87.0%) compared with all in
situ profiles. This class represented 10% of the patient
profiles and had a 16.5% likelihood to experience TD
of more than 30 days.
In situ class 3, or the medium-high TD in situ profile (32% of subsample), with a 17.8% likelihood of
TD of more than 30 days, had the highest conditional probabilities of being male (67.8%), married
(83.7%), and 50 to 74 years old (61.6%) at the time
of diagnosis with public health insurance (95.5%).
Class 3 had the highest conditional probabilities of
being White (95.2%) and residing in an Appalachian
county (57.5%).
Class 4, or the highest TD in situ profile (13% of
subsample), had a 19.3% likelihood of delaying treatment for more than 30 days. This profile group had
the highest conditional probabilities of being female
(82.4%), aged 75 to 84 years (50.1%) and 85 years
and older (24.0%), widow/widowed (94.3%), and
had public health insurance (95.6%) compared with
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TABLE 3
Treatment Delay Conditional Probabilities of In Situ CRC Patients (N = 1286)a

Sex/gender
Male
Female
Age
<50 y
50-74 y
75-84 y
≥85 y
Marital status
Single, never married
Married/common law
Divorced/separated
Widow/widower
Health insurance
No insurance/self-pay
Public insurance
Private insurance
Race
White
Black
Other
County of residence
Non-Appalachian
Appalachian
Treatment delay
≤30 d
>30 d

Class 1: Lowest
Treatment Delay
(N = 575; 45%)

Class 2:
Medium-Low
Treatment Delay
(N = 133; 10%)

Class 3:
Medium-High
Treatment Delay
(N = 409; 32%)

Class 4: Highest
Treatment Delay
(N = 169; 13%)

0.557
0.443

0.478
0.522

0.678
0.322

0.176
0.824

0.146
0.854
0.000
0.000

0.102
0.859
0.039
0.000

0.000
0.616
0.338
0.046

0.000
0.259
0.501
0.240

0.127
0.686
0.162
0.025

0.331
0.482
0.173
0.015

0.067
0.837
0.043
0.052

0.018
0.000
0.039
0.943

0.033
0.462
0.505

0.036
0.583
0.381

0.000
0.955
0.045

0.002
0.956
0.041

0.949
0.035
0.016

0.000
1.000
0.000

0.952
0.048
0.000

0.809
0.181
0.010

0.461
0.539

0.870
0.130

0.425
0.575

0.509
0.491

0.876
0.124

0.835
0.165

0.822
0.178

0.807
0.193

Abbreviation: CRC, colorectal cancer.
a Conditional probabilities range from 0 to 1 where the lighter to darker shades indicate an increasing likelihood.

all in situ profiles. Class 4 had high conditional possibilities of being White (80.9%), followed by Black
(18.1%), and living in either a non-Appalachian
county (50.9%) or an Appalachian county (49.1%).
See Table 3 for all conditional probabilities.

Latent class analysis on malignant subgroups
treatment delay
A 3-class solution with an entropy of 0.71 (N =
34 126) was the best-fitting model for the malignant
CRC TD analysis (Table 4). Class 1, or the lowest TD
malignant profile (57% of subsample), had a 20.6%
likelihood to delay surgical treatment for more than

30 days from diagnosis. Malignant class 1 profile had
the highest conditional probabilities of being White
(97.5%), male (60.0%), between 50 and 74 years of
age (80.0%), married (70.9%), on private health insurance (41.6%), and residing in Appalachian county
(53.9%).
Class 2, or the medium TD malignant profile (31%
of subsample), had a 25.4% likelihood to delay
surgery (>30 days). This class had the highest conditional probabilities of being female (60.4%), between
75 and 84 years of age (50.5%), a widow/widower
(47.9%), and on public health insurance (96.5%).
This profile had high conditional probabilities of being White (90.0%).

E492

Montiel Ishino, et al • 28(2), E487–E496

Latent Class Analysis on Tennessee Cancer Registry Data

TABLE 4
Treatment Delay Conditional Probabilities of Malignant CRC Patients (N = 34 126)a

Sex/gender
Male
Female
Age
<50 y
50 to 74 y
75-84
≥85 y
Marital status
Single, never married
Married/common law
Divorced/separated
Widow/widower
Health insurance
No insurance/self-pay
Public insurance
Private Insurance
Race
White
Black
Other
County of residence
Non-Appalachian
Appalachian
Treatment delay
≤30 d
>30 d

Class 1: Lowest
Treatment Delay
(N = 19 534;
57%)

Class 2: Medium
Treatment Delay
(N = 10 607;
31%)

Class 3: Highest
Treatment Delay
(N = 3985; 12%)

0.600
0.400

0.396
0.604

0.525
0.475

0.169
0.800
0.030
0.002

0.000
0.301
0.505
0.194

0.186
0.748
0.056
0.010

0.141
0.709
0.130
0.020

0.055
0.420
0.046
0.479

0.372
0.405
0.161
0.063

0.063
0.521
0.416

0.001
0.965
0.034

0.116
0.589
0.296

0.975
0.012
0.013

0.900
0.094
0.006

0.102
0.867
0.032

0.461
0.539

0.499
0.501

0.913
0.087

0.794
0.206

0.746
0.254

0.706
0.294

Abbreviation: CRC, colorectal cancer.
a Conditional probabilities range from 0 to 1 where the lighter to darker shades indicate an increasing likelihood.

Class 3, or the highest TD malignant profile,
represented 12% of the subsample, with a 29.4% likelihood of TD (>30 days). This profile had the highest
conditional probabilities of being both single/never
married (37.2%) and divorced/separated (16.1%),
Black (86.7%), having no health insurance or were
self-pay (11.6%), and residing in a non-Appalachian
county (91.3%). Malignant class 3 profile had high
conditional probabilities of being 50 to 74 years old
(74.8%) and on public health insurance (58.9%).
See Table 4 for all conditional probabilities. The
Figure provides a comparison of the distal outcomes of TD by patients with in situ and malignant
CRC.

Discussion
Racial/ethnic disparities in CRC incidence, mortality,
and survival vary significantly across the United
States. It is not clear whether early initiation of
treatment (≤30 days) improves survival outcomes.
Although a systematic review of 40 studies that
assessed the influence of therapeutic delay on CRC
indicated that the majority of the findings did not observe a relationship between early treatment initiation
and survival,27 few studies exist to understand the
problem. This study applied LCA, a person-centered
method, to identify risk profiles of surgical TD
among in situ and malignant CRC cohorts diagnosed
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FIGURE Treatment Delay Comparison of Patients With In Situ or Malignant Colorectal Cancer

from 2005 to 2015 in Tennessee. Our definition for
TD (>30 days) is consistent with other studies.14-16
The analysis of more than 35 000 patients showed
substantial differences in TD between in situ and malignant CRC patients with regard to age, sex/gender,
race, and Appalachian residence. Our LCA identified
4 in situ and 3 malignant risk profiles of CRC surgical
TD among patients.
We identified among patients with CRC most likely
to TD for more than 30 days were women 50 years or
older, widowed, and on public health insurance with
in situ diagnosis compared with those with a malignant diagnosis who were Black, between 50 and 74
years of age, on public health insurance, and residing
in non-Appalachian counties (Tables 3 and 4). Conversely, patient profiles with lowest risk or TD of 30
days or less among in situ and malignant CRC patients
were similar. That is, both in situ and malignant class
1 patients were predominantly male, aged 50 to 74
years, married/common law partnership, and White.
Nuanced differences were observed in private health
insurance; however, both had the highest conditional
probabilities within their respective cancer staging.
Regarding the in situ CRC-specific stage profiles,
class 1 had the lowest risk of TD, which contrasted
the highest TD risk profile of class 4 that was predominantly White widowed women, aged 75 to 84
years, and on public health insurance (Table 3). This
is in stark contrast to patient profiles with malignant
CRC in which the highest TD risk profile was among
Blacks (Table 4). Moreover, among the risk profiles
of patients with malignant CRC, the medium surgical TD was that of White women widows on public
health insurance and between 75 and 84 years of
age. As such, our findings not only identified similarities and differences between patients with in situ
and malignant CRC but also observed racial and gender disparities in surgical TD. These findings are in
line with prior studies reporting that Black patients
compared with Whites experienced longer time to TD

and are unlikely to receive recommended treatment
due to differences in health insurance coverage.41,44,45
Consistent with our results on single/never married and widowed experiencing delay (Tables 3 and
4), previous research has shown that differences in
CRC TD depend on many factors, including SES, access to care, and family support/background.10,17,45-47
Tramontano et al10 found significantly lower treatment recipients among patients with CRC who were
non-Hispanic Blacks, unmarried, and of low SES.
In addition, non-Hispanic Blacks and stage IV patients had the highest relative cost ratios for surgery,
radiation, and chemotherapy treatments during all
treatment phases.10 Hines and Markossian47 also reported that Blacks had a 40% increased odds of
late-stage CRC diagnosis, a 50% decreased odds of
having surgery for colon cancer, and a 67% decreased
odds of receiving surgery for rectal cancer compared
with Whites. Tawk et al3 also reported increased odds
of late-stage CRC in non-Hispanic Blacks, uninsured,
and Medicaid patients. Furthermore, lack of social
networks and support system, a prominent concern
for widowed and older patients, has been reported
to be associated with TD and poor prognosis due to
their inability to discuss symptoms and receive encouragement and health advice/support from family
and friends.17,48,49 Evidence indicates that disparities
exist in cancer incidence, treatment quality, mortality, and survival between Black and White despite
the mixed findings on the association between DTIs
and CRC outcomes.4,6,7,41,45 A recent study from Tennessee showed that Blacks were less likely than Whites
to receive CRC adjuvant treatment,41 while an earlier
report did not find the relationship between race and
treatment outcome.50
While CRC outcomes may not be predicted
by surgical TD, we still identified disparities by
way of surgical TD profiles. These profiles were
marked by a constellation of social determinants and
the Appalachian/non-Appalachian divide. Currently,
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there is a large gap in the cancer incidence literature
for Tennessee, especially while accounting for the Appalachian regions within. Through our findings, we
can best adapt existing CRC prevention programs in
Tennessee to address the possible determinants that
affect patients in providing access to quality health
care in order to mitigate surgical TD. Possible interventions to improve access could include patient
navigation and personalized medical care to include
cultural empathy and appropriate health literacy. In
addition, we can identify possible areas within Tennessee that need further exploration and examination
to understand the true context and disparities of CRC.
For instance, in the current study, we found Black
residents in non-Appalachian Tennessee with public insurance who had malignant CRC waited more
than 30 days to receive treatment. As such, a public health priority is to understand the role of social
determinants in the non-Appalachian as well as Appalachian contexts in Tennessee, thereby identifying
and examining the disparities propagating TD within
subpopulations.
Moreover, we propose to further focus on the Appalachian and non-Appalachian CRC TD disparity to
understand the nuanced differences between those regions in the context of urban, rural, and remote areas.
Prior studies in Appalachian states have found that
cancer incidence and mortality are disproportionate
in non-Appalachian areas when compared with Appalachian areas, and vice versa (eg, prostate cancer).35
Future studies will explore this association in greater
detail in Tennessee to help inform possible CRC interventions and preventive programs. We will specifically
identify CRC patient survivorship profiles once data
are made available by the TDH. The purpose of which
will be to compare whether TD profiles are similar or
dissimilar by survivorship as well as identify disparities by survivorship. In this manner, we can identify
what observed indicators may be salient in targeting
TD and improving survivorship for Tennessee’s patients with CRC to mitigate disparities and improve
quality of life.
While we observed possible inequities due to geography and race, to meaningfully address CRC health
disparities and inequities, we must go beyond Census
Bureau categories of race/ethnicity. Biomarker data
in the geographic context of socioeconomic and
ecological factors would be critical to understand the
dynamic relationship of person-level interaction to
cancer outcomes. Data on behavioral and health
risk factors, as well as comorbidities, would also be
beneficial to identify higher at-risk groups, as well as
improve our ability to identify risk profiles to further
personalized medicine and treatment. Future policies regarding cancer registries should include more

Latent Class Analysis on Tennessee Cancer Registry Data

holistic data collection to understand risk in context
to prevent cancer health disparities to move toward
health equity. By collecting CRC data contextually,
we can move from linearized categorizations and
assessments to targeted person-centered risk profiles
and preventive care.

Limitations
This study is among the first to examine TD patient
profiles within in situ and malignant CRC groups
using LCA. Furthermore, it adds to the current limited knowledge on CRC surgical TD by assessing and
identifying risk profiles of patients in a unique geographical region, currently not covered in the SEER
program.51 Although this study using standard and
validated measures involved a large population of
CRC patients not in the SEER program, there were
few limitations. First, we were limited by the retrospective administrative variables available to us. For
instance, cancer registries do not collect vital measures of SES data such as income and education, and
quality of treatment received by patients. In addition, some demographic variables collected may not
be up to date since these variables are only collected at
the time of diagnosis. Furthermore, despite the large
sample size, the results may not be generalizable to

Implications for Policy & Practice
Our analyses revealed disparities in both in situ and malignant
CRC patients; however, the disparity was more apparent among
malignant CRC patients than in situ CRC patients. Cancer control
and prevention, as well as care providers, in Tennessee should
be mindful that:
■ Blacks, public insurance holders, and non-Appalachian res-

idents had the highest likelihood of TD in malignant CRC
patients, while White widowed females residing in Appalachian and non-Appalachian counties, 75 years or older,
and public insurance holders had the highest likelihood of TD
among in situ CRC patients.
■ These disparities in CRC surgical TD may explain differ-

ences in health outcomes among Blacks who are most at
risk and while structural factors, clinical care, and treatment
outcomes may play a role in these delays, they were not
available for analysis.
■ The

use of person-centered approaches can help
public health researchers better detect cancer risk
profiles/subgroups, and the underlying determinants
of health that may be often overlooked, to help tailor
interventional programs for specific risk profiles and
efficiently/efficaciously address CRC disparities.
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other regions or the entire US population because
the data are from the TCR covering only residents
of Tennessee. Nevertheless, the findings are important because they provide a better understanding of
cancer health disparities within profiles of CRC TD
in Tennessee.

Conclusion
While our findings are not meant for diagnostic purposes, we found that Blacks were lower in TD with
in situ CRC; yet, the opposite was found in the malignant profiles where they had the highest TD. Although
TD is not a definitive marker of survival, we observed
that underserved/underrepresented groups are overrepresented in the highest TD profiles. The observed
disparities could be indicative of intervenable risk,
whereby person-centered approaches in conjunction
with cancer registry data can help in the development
of effective and efficacious prevention programs.
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